

**R&D MAGAZINE SELECTS XOFT AXXENT® ELECTRONIC BRACHYTHERAPY SYSTEM AS EDITOR'S CHOICE INNOVATION AWARD WINNER**

**Xoft Axxent® Miniature Brachytherapy X-ray Source Recognized as Most Innovative New Product of the Year**

**SUNNYVALE, Calif., March 18, 2009** – Xoft, Inc. today announced that R&D Magazine selected the Axxent® High Dose Rate (HDR) X-ray Source as Editor's Choice Most Innovative New Product of 2008. The award was announced at the recent R&D 100 Awards ceremony, where the Xoft system was recognized as one of the year's most technologically significant products. Established by the editors of R&D Magazine in 1963, the R&D 100 Awards are designed to recognize significant technological achievements and products that leapfrog current technology and that provide simple, elegant solutions to complex or long-standing technical or practical problems.

“Over the years, R&D Magazine has recognized innovation and impact from products and technologies that have gone on to become household names, such as the ATM, the fax machine, the Kodak photo CD, HDTV and the Nicoderm anti-smoking patch. Being recognized by the editors of this prestigious R&D Magazine as the most innovative new product is a tremendous honor,” said Paul Lovoi PhD, CTO and co-founder of Xoft. “This further validates that the Axxent miniature X-ray source is a fundamentally new way to deliver therapeutic radiation - one that we believe is the enabling technology for many generations of increasingly more sophisticated, accurate, and accessible radiation treatment systems.”

As a platform technology, the Axxent System addresses a variety of oncological and non-oncological indications. The Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Designed to deliver electronic, X-ray-based radiation treatment, the proprietary Axxent treatment platform can be used in many clinical settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety. As a result, tens of thousands of patients annually will have greater access to therapy that is delivered more easily and conveniently. Previously cleared for accelerated treatment of early stage breast cancer and endometrial and rectal

cancers, the Axxent System is also cleared for use in the treatment of surface cancers or conditions where radiation therapy is indicated.

“We were pleased to have the Axxent System included in the R&D 100, but to be named by the editors as the most innovative new product of the year is a testament to the hard work and dedication of the entire Xoft organization to bring this critical cancer treatment to market,” said Michael Klein, president and CEO of Xoft. “Combined with growing utilization of Electronic Brachytherapy for the treatment of breast and endometrial cancers, this continues to validate the paradigm shifting capabilities of this innovative technology.”

To learn more about the R&D 100 Awards, visit [www.RDmag.com](http://www.RDmag.com).

**About Xoft, Inc.**

Xoft, founded in 1998, develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. Xoft provides a “point of care model” that is patient centric and accessible to a broader spectrum of patients and their physicians. The Axxent treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the complex handling, resource logistics and costs associated with using radioactive isotopes. Xoft aligns with the Nuclear Regulatory Commission’s (NRC) directive to seek alternatives for radioactive medical isotopes. Commercially available for treatment of early stage breast cancer, endometrial, skin and surface indications, the Axxent® Electronic Brachytherapy System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. For more information, visit [www.xoftinc.com](http://www.xoftinc.com).

# # #

Axxent is a registered trademark of Xoft, Inc.

**Media Contact:**

Chris K. Joseph

Xoft, Inc.

510/339-2293

[chris@ckjcomm.com](mailto:chris@ckjcomm.com)